GlassScriptPhysician profile
Stacy P Thomas
NPI 1972865871
$1,770.09
in general payments reported to CMS, 2019-2025
25 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $182 · 2023: $604 · 2024: $286 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,326 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.10 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $283.01 | 2025 | Relistor |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $269.56 | 2022-2023 | |
| Abbvie INC. | $202.04 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $122.09 | 2021-2023 | Abilify Maintena |
| Edwards Lifesciences Corporation | $113.73 | 2024 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $111.44 | 2022-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $102.19 | 2025 | |
| Viiv Healthcare Company | $93.67 | 2024 | |
| Supernus Pharmaceuticals, INC. | $49.15 | 2023 | Qelbree |
| Novo Nordisk INC | $49.10 | 2021 | |
| Lundbeck LLC | $41.29 | 2023-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $40.06 | 2022-2023 | Ingrezza |
| Tris Pharma INC | $36.82 | 2023 | Dyanavel Xr |
| Pfizer INC. | $35.33 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.28 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $24.69 | 2025 | |
| Alkermes, INC. | $23.37 | 2023 | Aristada, Lybalvi |
| Scilex Pharmaceuticals INC. | $21.46 | 2025 | |
| Indivior INC. | $19.62 | 2023 | Perseris |
| Astellas Pharma US INC | $19.36 | 2021 | |
| Medtronic, INC. | $19.28 | 2025 | Inceptiv |
| Boston Scientific Corporation | $18.01 | 2025 | Wavewriter Alpha Prime 16 |
| Vertex Pharmaceuticals Incorporated | $15.97 | 2025 | |
| Glaxosmithkline, LLC. | $14.76 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.